Browse the evidence

Newer diabetes medications, specifically GLP-1 receptor agonists (like tirzepatide) and SGLT2 inhibitors, facilitate diabetes remission through significant weight loss and glycemic control, though long-term remission data is still emerging.

Newer drugs like tirzepatide and GLP-1 agonists can achieve high remission rates (up to 81%) by combining weight loss with hormonal effects. However, they are expensive, require injections, and long-term remission data is still being gathered. They are a safer alternative to surgery for some, but not a guaranteed cure.

In young adult men, a longer daily eating window is associated with higher insulin resistance (HOMA-IR) and a worse cardiometabolic risk score, while a shorter time from midsleep to first food intake (earlier eating) is associated with better cardiometabolic health.

For young men, how you time your food matters for metabolic health even if it doesn't change your weight. Try to keep your daily eating window shorter (avoid grazing all day) and eat your first meal closer to when you wake up. This pattern is linked to better insulin sensitivity and lower cardiometabolic risk.

Public perception of GLP-1 receptor agonists (GLP-1 RAs) on social media is predominantly neutral-to-positive, driven by reported weight loss efficacy and positive psychological impacts, despite awareness of side effects.

Social media discussions about GLP-1 drugs are largely positive, focusing on weight loss and mental health benefits, though side effects and access issues are common concerns. Patients should be aware that while public sentiment is favorable, individual experiences with side effects and availability vary significantly.

Combining GLP-1 receptor agonists with other Nutrient Stimulated Hormones (NuSH) like glucagon or amylin, or using dual/triple agonists like tirzepatide, may result in less lean mass loss compared to single-agonist GLP-1 treatments.

If you are on semaglutide and worried about muscle loss, ask your doctor if tirzepatide (a dual GLP-1/GIP drug) might be a better option for you, as it appears to spare more muscle. Newer triple-agonist drugs are also in development.

GLP-1 receptor agonists (GLP-1 RA) are associated with significant weight regain after discontinuation, whereas non-GLP-1 related treatments did not show statistically significant regain in this meta-analysis.

If you are on a GLP-1 medication (like semaglutide or liraglutide), stopping it is likely to cause significant weight regain due to the loss of appetite suppression. Other drugs may not show this same statistical pattern of regain in this analysis, but individual responses vary.

Persistent, intrusive, and dysphoric thoughts about food (food noise) are a distinct psychological construct that can be significantly reduced by GLP-1 receptor agonists, leading to improved quality of life and weight management outcomes.

If you experience constant, intrusive, and unpleasant thoughts about food that interfere with your life, this may be 'food noise,' a distinct psychological construct. GLP-1 receptor agonists (like semaglutide) have been shown to significantly reduce this noise, leading to better weight loss outcomes and improved quality of life. This is not a failure of willpower but a treatable condition.

GLP-1 receptor agonists (GLP-1 RAs) are prescribed for Type 2 Diabetes (ADM) and obesity (AOM), with semaglutide being the most commonly prescribed agent overall.

GLP-1 RAs like semaglutide are widely prescribed for diabetes and weight management. If you are considering this treatment, discuss insurance coverage and potential costs with your healthcare provider, as access can be limited by these factors.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a high signal for gastrointestinal adverse events (specifically gastroesophageal reflux disease and dyspepsia) and injection site reactions in real-world post-marketing data, alongside unexpected signals for increased appetite and food craving.

If you are taking tirzepatide, expect gastrointestinal issues like reflux or dyspepsia and injection site reactions (pain, bruising) to be common. Interestingly, while the drug is designed to suppress appetite, some users report increased appetite or food cravings in real-world reports. Monitor your blood glucose if you have diabetes, and report severe abdominal pain (pancreatitis risk) or severe injection site bleeding to your doctor immediately.

Semaglutide treatment significantly reduces body weight and BMI in patients with acquired hypothalamic obesity, with effects stabilizing after 12 months.

For patients with hypothalamic obesity, semaglutide (weekly injection) is an effective treatment for significant weight loss, even with prior hypothalamic damage. Treatment should be titrated to a tolerated dose (up to 2.5 mg), and patients should be aware that stopping treatment leads to rapid weight regain, so adherence and side-effect management are critical.

Phentermine/Topiramate combination therapy significantly reduces the rate of weight regain in patients who have undergone Roux-en-Y gastric bypass (RYGB).

If you are regaining weight after gastric bypass, ask your doctor about Phentermine/Topiramate. It is an oral medication that can help slow down weight regain. It requires a gradual dose increase to minimize side effects like dry mouth or tingling. While not as new as GLP-1 drugs, it has shown promise in keeping weight off in the years following surgery.

Deprescribing GLP-1 agonists in patients with Type 2 Diabetes does not result in weight regain or loss of glycemic control if the patient maintains Carbohydrate Restricted Nutrition Therapy (CRNT) supported by continuous remote care.

If you are taking a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes, you may be able to stop the medication without regaining weight or losing blood sugar control, provided you switch to a strict low-carbohydrate diet (under 30g carbs/day) and maintain nutritional ketosis. This approach mimics the drug's hormonal effects on hunger and satiety. You should work with a healthcare provider to monitor your progress and determine if you are a candidate for deprescription.

Carbohydrate Restricted Nutrition Therapy (CRNT) induces hormonal changes (lower ghrelin, higher GLP-1/CCK) that reduce hunger and appetite, thereby supporting weight maintenance after GLP-1 deprescription.

The reason low-carb diets help you stay full is not just willpower; they biologically alter your hunger hormones. Ketosis lowers ghrelin (the hunger hormone) and increases satiety hormones, making it easier to maintain weight loss without constant hunger.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GLP-1/GIP agonists (tirzepatide) are the most promising pharmacological treatments for obesity in older adults, offering favorable efficacy and safety profiles, though specific guidelines are currently lacking.

For older adults with obesity, GLP-1 agonists like liraglutide and semaglutide are currently the most effective pharmacological options. They work by mimicking hormones that regulate appetite and blood sugar. While they cause significant weight loss, there is a risk of muscle loss, so these medications should ideally be used alongside resistance exercise and adequate protein intake. Start with a low dose and increase slowly to manage stomach side effects. Note that data for those over 75 is limited.

Oral semaglutide administration in patients with type 2 diabetes significantly reduces body weight, HbA1c, and total cholesterol within 3-6 months, with additional systolic blood pressure reduction observed by 6-12 months.

If you have Type 2 Diabetes, oral semaglutide can significantly improve your weight, blood sugar (HbA1c), and cholesterol levels within the first 6 months, with blood pressure improvements continuing up to a year. While gastrointestinal side effects like nausea are common and may lead some to stop the medication, serious safety issues were not observed in this real-world study. It serves as a viable alternative to injectable GLP-1s, particularly for those who prefer oral medication or have needle phobia.

GLP-1 receptor agonists may improve psoriasis symptoms (PASI score) in patients with Type 2 Diabetes, though evidence from randomized controlled trials is mixed.

If you have psoriasis and Type 2 Diabetes, GLP-1 medications might help improve your skin symptoms, but this is not guaranteed. The most reliable benefit is the protection against heart disease and stroke. Discuss with your doctor if the potential skin benefits, combined with cardiovascular protection, outweigh the need for an injection.

Once-weekly subcutaneous administration of the glucagon/GLP-1 receptor co-agonist NNC9204-1177 produces dose-dependent, clinically significant body weight loss in adults with overweight or obesity, but is associated with unacceptable safety concerns including increased heart rate, hepatic disturbances, and impaired glucose tolerance.

This specific drug (NNC9204-1177) is not available for clinical use because it caused unacceptable side effects like increased heart rate and liver issues, despite causing significant weight loss. However, it highlights that combining GLP-1 and glucagon pathways can lead to substantial weight loss, which is why other approved GLP-1 medications exist. If you are considering GLP-1 therapy, discuss the specific safety profile of the approved options with your healthcare provider.

Oral semaglutide (up to 7 mg/day) produces significant weight loss (mean 4.5 kg) and BMI reduction in psychiatric patients with antipsychotic-induced weight gain over 16 weeks, with a safety profile comparable to metformin.

For psychiatric patients struggling with weight gain from antipsychotics, oral semaglutide is a viable treatment option. Start with 3 mg daily for the first month, then increase to 7 mg daily if tolerated. Expect about 4.5 kg (10 lbs) of weight loss over 4 months. Side effects like nausea are common but usually mild and go away. This treatment does not worsen psychiatric symptoms and may even improve quality of life.

Combined blockade of GDF8 (myostatin) and Activin A using monoclonal antibodies significantly increases lean muscle mass and decreases fat mass in postmenopausal women, with effects reversing to baseline upon cessation of treatment.

For postmenopausal women seeking to increase muscle mass, blocking both myostatin and activin A via antibody therapy produces significant muscle growth and fat loss. However, this effect is not permanent; stopping treatment leads to a return to baseline muscle size within about 6 months. The treatment requires regular IV infusions and carries mild side effects like muscle spasms. It is not a lifestyle intervention but a medical therapy requiring clinical supervision.

Female resistance-trained athletes tend to spare more lean mass than males during caloric restriction, potentially due to differences in training experience, pre-diet volume, and energy deficit.

Female athletes may naturally preserve muscle better during a cut than males, but they should still prioritize high training volume to maximize this benefit.

Tirzepatide demonstrates superior efficacy compared to Semaglutide in reducing HbA1c levels, but shows no clear superiority in weight loss or FBS reduction.

If your current Semaglutide treatment is not lowering your HbA1c enough, switching to Tirzepatide may provide better blood sugar control. However, do not expect significantly more weight loss from this switch, as both drugs appear to offer similar weight reduction benefits in this analysis.

Switching from Liraglutide to Semaglutide results in significant additional weight loss and FBS reduction, but does not significantly impact HbA1c levels.

If you are currently on Liraglutide and struggling with weight or fasting blood sugar, switching to Semaglutide may help you lose more weight and lower your FBS. However, this switch is unlikely to significantly improve your HbA1c levels.

GLP-1 receptor agonists facilitate significant weight loss and metabolic improvement in non-pregnant women, but current evidence does not demonstrate that pre-pregnancy use improves pregnancy outcomes and may be associated with increased gestational weight gain.

GLP-1 drugs like Semaglutide cause significant weight loss in women with obesity. However, because there is no proof they improve pregnancy outcomes and animal studies suggest potential fetal growth restriction (likely due to maternal weight loss/nutrition), they are not currently recommended for improving pregnancy success. Women using these drugs should use effective contraception and stop the medication at least 6 weeks before trying to conceive, as advised by current guidelines.

Combining semaglutide with cilofexor or firsocostat improves liver steatosis more than semaglutide monotherapy in patients with NASH and mild-to-moderate fibrosis, without significantly affecting liver stiffness.

For patients with mild-to-moderate NASH fibrosis, adding cilofexor or firsocostat to semaglutide treatment can reduce liver fat more effectively than semaglutide alone. However, this combination does not appear to improve liver stiffness (fibrosis) and involves taking multiple daily medications alongside weekly injections.

Oral semaglutide (up to 14 mg daily) significantly reduces liver steatosis, liver enzymes, and body weight in patients with NAFLD and Type 2 Diabetes, correlating with weight loss.

Oral semaglutide (up to 14 mg daily) is an effective treatment for NAFLD in patients with Type 2 Diabetes, significantly reducing liver fat and enzymes. The benefits are closely linked to weight loss, and side effects are generally manageable with dose escalation.